Minutes: Steering Board meeting, 2 and 6 October 2020

1. Strategic discussion about expanding the current portfolio of 6+1

A number of MSs pleaded for a broader Portfolio and for the continuation of discussions and possible negotiations with companies beyond the 6+1.

Some Member States asked for more information, including on the financial consequences, of a boarder portfolio.

[Name] concluded that a discussion on how approach strategically a future expansion of the current portfolio of 6+1 would be held at the next meetings of the Steering Board.

2. EEA file- final status

The Commission confirmed that the date for sending the binding allocation to AstraZeneca would be the [ ] October. This date would trigger [Name] for the Member States to sign and enter the Order Forms.

The Members States were also informed on various aspects and documents relevant for the implementation of the contract (logistics, transport, number of does etc.).

The Commission reminded the Members that the allocation would have [Name] from [Name] 2020 until [Name] 2021.

The Commission also followed up briefly with information on [Name] provisions.

3. Update on other contracts in [Name] / discussions with other companies

SANOFI- the signed version of the contract was transmitted to the Member States via the secured transmission.

J&J –work progresses towards the finalisation of the contract in the course of next week. The Members were informed that an extraordinary Steering Board meeting would be conveyed in the following days, in order to keep the Members informed of the latest developments on the APA negotiations ahead of its conclusion.

Curevac – the Members were reminded that a second scientific presentation took place in the course of the week.
Moderna – are with the process.

BioNTech - the is to be constituted in the forthcoming days.

The exploratory discussions were nearly finalized leaving the next steps up to the Member States’ political decision. Members were informed on key elements of discussion such as: price, payments including upfront ones, number of doses, foreseen marketing authorisation etc.

Valneva - the Members were informed on the discussions regarding the number of doses.

4. Marketing authorisation: centralised procedure vs. national procedure

The Commission explained the rules and procedures regarding the marketing authorisation at EU and national level.

The presentation outlined that the centralised procedures (authorisation by the Commission based on a scientific opinion of the European Medicines Agency) would lead to vaccines being authorised and marketable to all the EU Member States, whereas national authorisation would limit their availability only to the MSs that granted the authorisation.

All COVID-19 vaccines are eligible for the centralised procedure, most under the mandatory scope and some under the optional scope.

All Member States that took the floor called against fragmented market authorisations, being in favour of central assessment and authorisation by EMA/Commission.
5. Exceptional Steering Board meeting on J&J contract- 6 October 2020

In a short dedicated session, the Member States were informed of the latest developments and the final outcome on the APA negotiations with J&J, ahead the conclusion of the contract.

The Commission informed the Members on key elements of the contract, such as:

- **The timeline of delivery** of the:
  - Base volume:
  - Additional volume:

- **Payment structure**: information was provided about the payment of the Commission and of the Member States.

- **Resale and donation provisions**: good provisions reflecting the company’s policy for optimal distribution at global level.

- **Distribution**: J&J will deliver to distribution hub Member State.

- **Type of contract**:.

- **Next steps**: after the endorsement by the College, the adopted contract will be transmitted to the Member States that will have 5 working days to notify if they intend to opt-out.